Roche's risdiplam clears another phase 3, setting up SMA showdown with Biogen and Novartis

Roche’s risdiplam has come through another late-phase test, triggering improvements in the motor skills of infants with type 1 spinal muscular atrophy. The clinical success comes months before the FDA is set to decide whether to approve the survival motor neuron-2 splicing modifier.